Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,690 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Men Clear all
Enrolling by invitation No phase listed Observational

Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men

NCT06472817
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 10:49 AM EDT
Withdrawn Phase 4 Interventional

Treating Nocturnal Hypertension and Nocturia in African American Men

NCT03319823
View directory record Official record
Conditions
High Blood Pressure
Interventions
Thiazide Treatment Group, Intensified Thiazide Treatment Group, Combination Medication Treatment Group
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 59 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial

NCT01839279
View directory record Official record
Conditions
Spasticity
Interventions
Tizanidine, Placebo, Moxifloxacin
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 31, 2026, 10:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Intervention to Help Orient Men to Excel (IN-HOME) Phase II Study

NCT07704060
View directory record Official record
Conditions
Caregivers, Community Health Workers, Knowledge, Attitude, Self-Efficacy, Intentions, Health
Interventions
Intervention to Help Orient Men to Excel (IN-HOME), Supplying Useful Perimenopause Through Post-menopause Online Resources and Tools (SUPPORT)
Behavioral · Other
Lead sponsor
KDH Research & Communication
Industry
Eligibility
18 Years and older · Male only
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

NCT01054079
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
laboratory biomarker analysis, quality-of-life assessment, questionnaire administration, cinacalcet hydrochloride
Other · Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Not applicable Interventional

HIV Prevention and Trauma Treatment for Men Who Have Sex With Men With Childhood Sexual Abuse Histories

NCT01395979
View directory record Official record
Conditions
Sexual Risk Behavior, Childhood Sexual Abuse, Stress Disorders, Post-Traumatic
Interventions
Cognitive Processing Therapy for Sexual Risk, Supportive Psychotherapy, Sexual Risk Reduction Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Coral Gables, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Examining the Effectiveness of the Nicotine Patch in Male and Female Smokers - 2

NCT00135746
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
nicotine transdermal system
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 31, 2026, 10:49 AM EDT
Withdrawn Phase 2 Interventional

Insulin Resistance and Androgen Deprivation Therapy

NCT04995978
View directory record Official record
Conditions
Prostate Cancer, Insulin Resistance
Interventions
Pioglitazone 30 mg, placebo tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

NCT00360425
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol, moxifloxacin, placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men

NCT01431079
View directory record Official record
Conditions
HPV Vaccine Acceptability
Interventions
HPV vaccine acceptability
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

NCT00002596
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions
bleomycin sulfate, filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older · Male only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
149
States / cities
Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 105 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

NCT03400488
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AZD5718 oral suspension, Placebo matching AZD5817 oral suspension
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

NCT04103450
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
31
States / cities
Huntsville, Alabama • Lincoln, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

NCT00647868
View directory record Official record
Conditions
Hypogonadism
Interventions
testosterone
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Not applicable Interventional Results available

Blueberry Consumption and Type 2 Diabetes

NCT02972996
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Blueberry, Placebo
Other
Lead sponsor
Albany Research Institute, Inc.
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ABG Oxidative Stress Study Protocol-1

NCT02213523
View directory record Official record
Conditions
Healthy
Interventions
Plant concentrate A, Plant concentrate B, Plant concentrate C, Plant concentrate D
Dietary Supplement
Lead sponsor
Access Business Group
Industry
Eligibility
45 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 31, 2026, 10:49 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

NCT06261840
View directory record Official record
Conditions
Trichomonas Vaginitis, Bacterial Vaginitis
Interventions
Metronidazole 500 mg, Secnidazole 2000 MG
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
4
States / cities
Birmingham, Alabama • North Miami, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 10:49 AM EDT
Terminated Phase 1 Interventional

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

NCT05999968
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Abemaciclib, Darolutamide, LHRH agonist/antagonist
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Springdale, Arkansas • Mineola, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men

NCT00431197
View directory record Official record
Conditions
Hypogonadism
Interventions
Ketoconazole, Dexamethesone, Androgel,GnRH
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

NCT02985957
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nivolumab, Ipilimumab, Cabazitaxel, Prednisone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
15
States / cities
Tucson, Arizona • Marietta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 1 Interventional

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

NCT03177460
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Testosterone Greater Than 150 ng/dL
Interventions
Daratumumab, FMS Inhibitor JNJ-40346527, Radical Prostatectomy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 31, 2026, 10:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

NCT00753220
View directory record Official record
Conditions
Prostate Cancer
Interventions
VDC2008, Cyclophosphamide
Biological · Drug
Lead sponsor
Bostwick Laboratories
Industry
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 31, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

NCT04100018
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nivolumab, Prednisone, Docetaxel, Placebo
Biological · Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 31, 2026, 10:49 AM EDT